TY  - JOUR
PY  - 2004//
TI  - Ecstasy: pharmacodynamic and pharmacokinetic interactions
JO  - Psychosomatics
A1  - Oesterheld, Jessica R.
A1  - Armstrong, Scott C.
A1  - Cozza, Kelly L.
SP  - 84
EP  - 87
VL  - 45
IS  - 1
N2  - At "raves," young people dance and ingest illicit drugs, the most common of which is MDMA (N-methyl-3,4,-methylenedioxymethamphetamine) or "ecstasy." This drug is metabolized principally through the cytochrome P450 (CYP450) 2D6 enzyme. Pharmacokinetic drug-drug interactions can occur if MDMA is combined with other recreational or therapeutic drugs that are 2D6 inhibitors. Ecstasy concentration may increase to cause toxicity. Since ecstasy is pro-serotonergic, it may also be involved in pharmacodynamic drug-drug interactions when other pro-serotonergic drugs are combined with it, leading to a central serotonin syndrome. Some drugs are both pro-serotonergic and CYP450 2D6 inhibitors and, if co-administered with ecstasy, may cause both pharmacokinetic and pharmacodynamic drug-drug interactions.<p /> <p>Language: en</p>
LA  - en
SN  - 0033-3182
UR  - http://dx.doi.org/10.1176/appi.psy.45.1.84
ID  - ref1
ER  -